

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification of This Application: Class 544
Subclass

Prior Application: Examiner Celia Chang
Art Unit 1625

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is a continuation under 37 C.F.R. 1.53(b), of pending prior Application Serial Number 10/151,211 filed on 20 May 02, of David B. Reitz, John P. Koepke, Edward H. Blaine, Joseph R. Schuh, Robert E. Manning and Glenn J. Smits, entitled Renal-Selective Prodrugs for Control of Renal Sympathetic Nerve Activity in the Treatment of Hypertension.

- ☒ Enclosed is a copy of the prior application, including the Oath of Declaration as originally filed. I hereby verify that the attached papers are a true copy of said prior application as originally filed on 20 May 02.
- ☐ Cancel in this application, original Claims of the prior application before calculating the filing fee. (At least one original, independent claim must be retained for filing purposes).
- ☒ Amend the specification by inserting before the first line the sentence: -- This is a continuation under 37 C.F.R. 1.53(b), of pending prior Application Serial Number 09/678,015 filed on October 2, 2000, which is a continuation of prior Application Serial Number 09/444,888 filed on November 22, 1999 which is a continuation of prior Application Serial Number 08/639,493 filed on April 29, 1996, now abandoned, which is a continuation of Application Serial Number 08/280,170 filed on July 25, 1994, now abandoned, which is a continuation-in-part of PCT/US90/04168 filed on July 25, 1990, which is a continuation-in-part of Application Serial Number 07/386,527 filed on July 27, 1989, now abandoned. --
- ☒ Preliminary Amendment

03917 U.S. PTO
10/689919
102003

[X] The filing fee is calculated below:

Basic Filing Fee [37 CFR 1.16(a)]			\$770.00	\$770.00
Additional Filing Fee [37 CFR 1.16(b), (c)]				
Claims	No. Filed	No. Extra	Rate	
Independent	<u>1</u> - 3 =		X \$86.00 =	0
Total	<u>110</u> - 20 =	90	X \$18.00 =	\$1620.00
TOTAL FEE:				\$2390.00

- [X] A triplicate copy of this transmittal paper is enclosed.
- [X] Please charge the above calculated total fee to my Deposit Account No. 19-1025.
- [X] The Commissioner is hereby authorized and requested to charge any fees in addition to the above as well as all future fees set forth in 37 CFR 1.16 and 1.17 which may be required during the entire pendency of this Application, and credit any overcharges to Deposit Account No. 19-1025 [37 CFR 1.25(b)].

**NOTE: THIS AUTHORIZATION DOES NOT
INCLUDE FEES REQUIRED UNDER 37 CFR 1.18**

- [x] Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. ANOTHER DUPLICATE COPY OF THIS SHEET IS ENCLOSED FOR FILING IN THE PRIOR APPLICATION FILE.
- [] New formal drawings are enclosed.
- [] Priority of Application Serial No. , filed on in (country) is claimed under 35 U.S.C. 119.
- [] The certified copy of the priority application has been filed in prior Application Serial No. , filed .
- [X] The prior application is assigned of record to G.D. Searle & Co., P.O. Box 5110, Chicago, Illinois 60680.
- [X] The Power of Attorney in the prior application is to J. Timothy Keane, Registration Number 27,808.
- [X] The power appears in the original papers in the prior application.
- [] Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- [] Enclosed is an Associate Power of Attorney from J. Timothy Keane to .


[X] Address all future communications to:

J. Timothy Keane
PHARMACIA CORPORATION
of Pfizer Inc.
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

16 Oct 03 Date:

Address of Signer:
Pharmacia Corporation
Of Pfizer Inc.
Mail Zone MC5
575 Maryville Centre Drive
St. Louis, MO 63141


J. Timothy Keane
Attorney for Applicants
Registration No. 27,808
314-274-9090



PATENT

C-2510/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

D.B. REITZ ET AL

SERIAL NUMBER: 10/151,211

FILED: 20 MAY 02

GROUP ART UNIT: 1625

EXAMINER: C. CHANG

DATE: 16 OCT 03

TITLE: RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC
NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Alexandria, VA 22313-1450 on 16 Oct 03
J. Timothy Keane
Registration No. 27,808

J. Timothy Keane Date: 16 Oct 03

EXTENSION OF TIME UNDER 37 C.F.R. 1.136(a)

Commissioner of Patents and Trademarks
Alexandria, VA 22313-1450

Sir:

This is a petition for an Extension of Time to extend the
due date for this response for a period of 3 months from
July 18, 2003 to October 18, 2003.

Please charge the appropriate extension fee to Deposit
Account No. 19-1025.

Respectfully submitted,

J. Timothy Keane
J. Timothy Keane
Attorney for Applicants
Registration No. 27,808
314-274-9090 (St. Louis)

PHARMACIA CORPORATION
of Pfizer Inc.
Corporate Patent Department
P. O. Box 1027
Chesterfield, MO 63006